All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to BuyZacks Investment Research · Oct 5, 2026
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026GlobeNewsWire · Oct 5, 2026
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head AnalysisDefense World · Oct 1, 2026
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisGlobeNewsWire · Sep 9, 2026
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 11, 2026
Autolus Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.21 | -$0.15 | Beat |
| May 14, 2026 | -$0.29 | -$0.27 | Beat |
| Mar 27, 2026 | -$0.26 | -$0.34 | Miss |
| Nov 12, 2025 | -$0.23 | -$0.30 | Miss |
| Aug 12, 2025 | -$0.24 | -$0.18 | Beat |
| May 8, 2025 | -$0.24 | -$0.26 | Miss |